ReleaseWire

Global Market Direct's pharmaceuticals report, "Ultragenyx Pharmaceutical Inc. - Product Pipeline Review - 2013" provides data on the Ultragenyx Pharmaceutical Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Biocon Limited - Product Pipeline Review - 2013" provides data on the Biocon Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Enterocolitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterocolitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterocolitis. Enterocolitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "VLP Biotech, Inc. - Product Pipeline Review - 2013" provides data on the VLP Biotech, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Hospital Acquired Pneumonia (HAP) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "PharmAbcine, Inc. - Product Pipeline Review - 2013" provides data on the PharmAbcine, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Quintessence Biosciences, Inc. - Product Pipeline Review - 2013" provides data on the Quintessence Biosciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Humanetics Corporation - Product Pipeline Review - 2013" provides data on the Humanetics Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Acute Inflammation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Inflammation. Acute Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Pluristem Therapeutics, Inc., a leading developer of placenta-based cell therapies, today announced the appointments of two of its senior executives. These executive appointments support the Company’s growth and opportunities both on the clinical development front and with its big-pharma corporate partnerships. This comes at a time when Pluristem is advancing its cell therapies for numerous indications through global clinical trials.

Global Market Direct's pharmaceuticals report, "Xenetic Biosciences plc - Product Pipeline Review - 2013" provides data on the Xenetic Biosciences plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata). Genital Warts (Condylomata Acuminata) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "PIQUR Therapeutics AG - Product Pipeline Review - 2013" provides data on the PIQUR Therapeutics AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "OncoImmune, Inc. - Product Pipeline Review - 2013" provides data on the OncoImmune, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Galapagos NV - Product Pipeline Review - 2013" provides data on the Galapagos NV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Chronos Therapeutics Limited - Product Pipeline Review - 2013" provides data on the Chronos Therapeutics Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "AltraVax Inc. - Product Pipeline Review - 2013" provides data on the AltraVax Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "centrose llc - Product Pipeline Review - 2013" provides data on the centrose llc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Medicure Inc. - Product Pipeline Review - 2013" provides data on the Medicure Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Furiex Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Furiex Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "reMYND - Product Pipeline Review - 2013" provides data on the reMYND's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Sanwa Kagaku Kenkyusho Co., Ltd. - Product Pipeline Review - 2013" provides data on the Sanwa Kagaku Kenkyusho Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Global Market Direct's pharmaceuticals report, "Anchor Therapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Anchor Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Pulmatrix, Inc. - Product Pipeline Review - 2013" provides data on the Pulmatrix, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.